May 8 |
Regenxbio (RGNX) Reports Q1 Loss, Lags Revenue Estimates
|
May 8 |
Regenxbio GAAP EPS of -$1.38 misses by $0.11, revenue of $15.62M misses by $7.9M
|
May 8 |
REGENXBIO Reports First Quarter 2024 Financial Results and Recent Operational Highlights
|
May 7 |
Regenxbio Q1 2024 Earnings Preview
|
May 1 |
REGENXBIO to Host Conference Call on May 8 to Discuss First Quarter 2024 Financial Results and Recent Operational Highlights
|
Apr 24 |
REGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
|
Apr 17 |
REGENXBIO Inc.'s (NASDAQ:RGNX) recent 7.9% pullback adds to one-year year losses, institutional owners may take drastic measures
|
Mar 28 |
REGENXBIO Sees Positive Results For Macular Degeneration Therapy
|
Mar 28 |
REGENXBIO Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMD
|
Mar 27 |
REGENXBIO to Participate in Cantor Fitzgerald's Virtual DMD and Other Dystrophy Days
|